证券代码：688578 证券简称：艾力斯 公告编号：2025-006 上海艾力斯医药科技股份有限公司 第二届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海艾力斯医药科技股份有限公司（以下简称"公司"）第二届董事会第十 四次会议于 2025 年 4 月 22 日在公司会议室以现场结合通讯方式召开。本次会议 由董事长杜锦豪先生召集并主持，全体董事出席会议。本次会议的召集和召开程 序符合《中华人民共和国公司法》等法律法规、规范性文件以及《公司章程》的 相关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 经与会董事审议，形成如下决议： （一） 审议通过《关于公司<2024 年年度报告>及其摘要的议案》 经与会董事审议，董事会同意通过《上海艾力斯医药科技股份有限公司 2024 年年度报告》及《上海艾力斯医药科技股份有限公司 2024 年年度报告摘要》。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）上的 《上海艾力斯医药科技股份有限公司 ...

证券代码：688578 证券简称：艾力斯 公告编号：2025-008 上海艾力斯医药科技股份有限公司 2024 年年度利润分配方案及 2025 年中期分红安排的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 （一）利润分配方案的具体内容 经安永华明会计师事务所（特殊普通合伙）审计，上海艾力斯医药科技股份 有限公司（以下简称"公司"）2024 年度合并财务报表归属于上市公司股东的净 1 每股分配比例：每 10 股派发现金红利人民币 4.0 元（含税）。公司不送红股， 不进行资本公积金转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将 在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总额不 变，相应调整每股分配比例，并将另行公告具体调整情况。 公司 2024 年年度利润分配方案不触及《上海证券交易所科创板股票上市规则》 第 12.9.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 本年度现金分红比例低于 ...

Financial Performance - The company's revenue for Q1 2025 reached ¥1,098,374,566.26, representing a 47.86% increase compared to ¥742,835,715.09 in the same period last year[4] - Net profit attributable to shareholders was ¥410,497,438.67, a 34.13% increase from ¥306,052,559.16 year-on-year[4] - Basic and diluted earnings per share increased to ¥0.91, reflecting a growth of 33.82% compared to ¥0.68 in the prior year[4] - Operating profit for Q1 2025 was RMB 477,078,629.83, compared to RMB 313,917,428.44 in Q1 2024, reflecting a 52.0% increase[21] - Total comprehensive income for Q1 2025 was RMB 346,738,605.88, slightly up from RMB 320,044,154.27 in Q1 2024[22] Research and Development - R&D investment totaled ¥112,129,230.35, up 74.86% from ¥64,126,011.92 in the previous year, accounting for 10.21% of revenue[4] - The company experienced a 43.08% increase in R&D expenses, driven by new clinical projects for Vomeprazole[7] - Research and development expenses increased to RMB 91,754,053.37 in Q1 2025, up 43.3% from RMB 64,126,011.92 in Q1 2024[21] - The company is advancing its clinical research with a newly approved Phase III trial for Furmetin, targeting non-small cell lung cancer patients with non-classical EGFR mutations[14] - The company is committed to developing innovative drugs to meet unmet clinical needs, focusing on First-in-class and Best-in-class therapies[14] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,234,673,159.21, a 5.38% increase from ¥5,916,131,448.10 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to RMB 6.235 billion, an increase from RMB 5.916 billion at the end of 2024[19] - The total liabilities decreased to RMB 597.48 million from RMB 633.32 million in the previous period[19] - The company’s retained earnings increased to RMB 1.621 billion, up from RMB 1.245 billion at the end of 2024[19] Cash Flow - The net cash flow from operating activities was ¥392,806,950.89, a 7.54% increase from ¥365,255,516.58 in the previous year[4] - Cash flow from operating activities for Q1 2025 was RMB 392,806,950.89, compared to RMB 365,255,516.58 in Q1 2024, indicating a positive trend[24] - The company reported a net cash outflow from investing activities of RMB -581,527,811.19 in Q1 2025, compared to a net inflow of RMB 468,725,625.83 in Q1 2024[24] - The company's cash and cash equivalents stood at RMB 588.61 million, slightly up from RMB 586.99 million at the end of the previous year[17] - Cash and cash equivalents at the end of Q1 2025 were RMB 333,136,530.30, down from RMB 1,917,563,295.01 at the end of Q1 2024[26] Marketing and Sales - The company reported a significant increase in sales expenses by 44.65% due to an expanded marketing team and promotional activities for its product, Vomeprazole[7] - The core product, Furmetin (甲磺酸伏美替尼片), saw continuous sales growth, benefiting an expanding patient population in China[13] - The marketing team is actively promoting the RET inhibitor Pralsetinib (普吉华○R), leveraging synergies from Furmetin's market development[13] - Total operating costs for Q1 2025 were RMB 641,306,439.50, an increase of 47.8% from RMB 433,988,956.35 in Q1 2024[21] Government Support - The company received government subsidies amounting to ¥2,294,972.60, contributing to a 165.26% increase in other income[6]

Financial Performance - The company achieved total revenue of CNY 3,557,930,155.88 in 2024, representing a year-on-year growth of 76.29%[27]. - Net profit attributable to shareholders reached CNY 1,429,847,078.92, an increase of 121.97% compared to the previous year[26]. - The basic earnings per share rose to CNY 3.18, reflecting a significant increase of 122.38% year-on-year[25]. - The weighted average return on equity improved to 29.26%, up by 11.29 percentage points from the previous year[25]. - Research and development investment amounted to CNY 481,531,337.51, increasing by 53.81% year-on-year, but the ratio to revenue decreased to 13.53%[28]. - The company implemented cost control measures, leading to a substantial increase in net profit despite rising revenues[27]. - Total assets grew by 35.18% year-on-year, reaching CNY 5,916,131,448.10 at the end of 2024[26]. - The net assets attributable to shareholders increased by 32.66% to CNY 5,282,813,244.35[26]. - The company maintained a strong cash flow from operating activities, with a net cash flow of CNY 1,566,013,461.28, up 132.12% year-on-year[26]. Dividend Distribution - The proposed cash dividend for the 2024 fiscal year is 292,500,000.00 yuan (including tax), which accounts for 20.46% of the net profit attributable to shareholders of the listed company[5]. - The company plans to distribute a cash dividend of 4.0 yuan (including tax) for every 10 shares, totaling 180,000,000.00 yuan (including tax) based on a total share capital of 450,000,000 shares as of December 31, 2024[4]. - The interim cash dividend for the first half of 2024 is set at 2.50 yuan (including tax) for every 10 shares, amounting to 112,500,000.00 yuan (including tax)[4]. - The board of directors has approved the profit distribution plan, pending approval from the 2024 annual general meeting[4]. Research and Development - The company is focused on developing new drugs for the treatment of non-small cell lung cancer, specifically targeting EGFR mutations[15]. - The company aims to enhance its research capabilities by collaborating with Contract Research Organizations (CROs) for drug development[14]. - The company is committed to achieving a Disease Control Rate (DCR) of over 60% in its clinical trials for new oncology drugs[14]. - The median Progression Free Survival (mPFS) is targeted to exceed 12 months in ongoing clinical studies[14]. - The company plans to submit Investigational New Drug (IND) applications for its leading candidates in the upcoming quarters[14]. - The company has established a comprehensive clinical trial program, including Phase I, II, and III trials, to evaluate the drug's pharmacokinetics and therapeutic effects[15]. - The company is actively conducting clinical trials to expand fumetinib's indications, including first-line and second-line treatments for various mutations[67]. - The company has developed two core technologies: drug molecular design and discovery technology, and metabolism-based drug design and optimization technology[99]. - The company has established a complete new drug R&D system over more than 20 years, focusing on innovative drug development as its core strategy[99]. Product Development and Pipeline - The company reported a new small molecule targeted anti-tumor drug, Fumetinib, which is primarily used for the treatment of advanced non-small cell lung cancer (NSCLC) with EGFR mutations[13]. - The drug has received approval from the National Pharmacopoeia Commission under the generic name Fumetinib tablets[13]. - The company is exploring strategic partnerships and potential acquisitions to bolster its pipeline and market reach[14]. - The company is actively developing AST2303 for treating EGFR C797S mutation advanced NSCLC, with clinical trial approval received in September 2024, currently in Phase I trials[40]. - The company signed a licensing agreement for KRAS G12C inhibitor Goretinib and SHP2 inhibitor AST24082, expanding its oncology pipeline to include treatments for lung, pancreatic, and colorectal cancers[45][46]. - The company is currently conducting a Phase III clinical trial for Furmonertinib in treating EGFR-sensitive non-squamous NSCLC patients with brain metastases, which received IND approval in July 2024[60]. - The company aims to continuously expand the clinical applications of its core product, Furmetinib, targeting various NSCLC indications, including adjuvant therapy and specific mutations[185]. Market and Competitive Landscape - The global oncology drug market size increased from $143.5 billion in 2019 to $228.9 billion in 2023, with a CAGR of 12.4%[85]. - The Chinese oncology drug market grew from RMB 182.7 billion in 2019 to RMB 241.6 billion in 2023, with a CAGR of 7.2%[85]. - The company faces single product dependency risk as Fumetinib will continue to be the main revenue contributor in the near future[121]. - The company is exposed to market competition risks with existing similar drugs already approved and others in various clinical trial stages[122]. - The company is at risk of future price declines for its products due to the competitive landscape and government-led centralized procurement policies[125]. Governance and Compliance - The company has improved its governance mechanisms and compliance management systems, achieving an "A" rating in information disclosure evaluation by the Shanghai Stock Exchange for the 2023-2024 period[49]. - The company is committed to improving its governance structure and internal management systems to ensure compliance with legal regulations and enhance operational efficiency[189]. - The board includes independent directors with extensive experience in finance, law, and academia, contributing to governance and oversight[200]. - The company is committed to maintaining transparency in its financial reporting and governance practices[200]. Talent and Workforce Development - The company is enhancing its talent acquisition and training systems, focusing on new drug development and clinical marketing to build a diverse and experienced team[48]. - The company emphasizes talent development, planning to strengthen its workforce by attracting various professionals and enhancing training systems to improve overall employee skills[188]. - The management team has extensive experience in the pharmaceutical industry, ensuring effective operations in new product development and quality assurance[117].

上海艾力斯医药科技股份有限公司 2024 年度 募集资金存放与实际使用情况专项报告 及鉴证报告 目录 页码 | 一、募集资金存放与实际使用情况鉴证报告 | | | 1 - | | 2 | | --- | --- | --- | --- | --- | --- | | 二、上海艾力斯医药科技股份有限公司 2024 | | 年度募集资金 | | | | | 存放与实际使用情况专项报告 | | | 3 - | | 11 | | 三、附表 | 1：2024 | 年度募集资金使用情况对照表 | 12 - | 14 | | | 附表 | 2：2024 | 年度变更募集资金投资项目情况表 | 15 - | 17 | | 募集资金存放与实际使用情况鉴证报告 安永华明（2025）专字第80013571_B03号 上海艾力斯医药科技股份有限公司 上海艾力斯医药科技股份有限公司董事会： 我们接受委托，对后附的上海艾力斯医药科技股份有限公司 2024 年度募集资金存 放与实际使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公司 监管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所科 创板上市 ...

上海艾力斯医药科技股份有限公司 2024年度财务报表及审计报告 上海艾力斯医药科技股份有限公司 2024年度财务报表及审计报告 | 内容 | 页码 | | | --- | --- | --- | | | 1 – | 7 | | 审计报告 | | | | 2024年度财务报表 | | | | 合并资产负债表 | 8 – | 9 | | 公司资产负债表 | 10 – | 11 | | 合并利润表 | 12 | | | 公司利润表 | 13 | | | 合并现金流量表 | 14 | | | 公司现金流量表 | 15 | | | 合并股东权益变动表 | 16 | | | 公司股东权益变动表 | 17 | | | 财务报表附注 | 18 – | 90 | | 财务报表补充资料 | 1 | | 审计报告 安永华明（2025）审字第80013571_B01号 上海艾力斯医药科技股份有限公司 上海艾力斯医药科技股份有限公司全体股东： 一、审计意见 我们审计了上海艾力斯医药科技股份有限公司的财务报表，包括2024年12月31日的合 并及公司资产负债表，2024年度的合并及公司利润表、股东权益变动表和现金流量表以及 相关财务报表 ...

关于上海艾力斯医药科技股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项说明 非经营性资金占用及其他关联资金往来情况的专项说明 安永华明（2025）专字第80013571_B02号 上海艾力斯医药科技股份有限公司 上海艾力斯医药科技股份有限公司董事会： 我们审计了上海艾力斯医药科技股份有限公司的2024年度财务报表，包括2024年 12月31日的合并及公司资产负债表，2024年度的合并及公司利润表、股东权益变动表 和现金流量表以及相关财务报表附注，并于2025年4月22日出具了编号为安永华明 （2025）审字第80013571_B01号的无保留意见审计报告。 按照《上市公司监管指引第8号——上市公司资金往来、对外担保的监管要求》的 要求，上海艾力斯医药科技股份有限公司编制了后附的2024年度非经营性资金占用及 其他关联资金往来情况汇总表（以下简称"汇总表"）。 如实编制和对外披露汇总表，并确保其真实性、合法性、完整性是上海艾力斯医 药科技股份有限公司的责任。我们对汇总表所载资料与我们审计上海艾力斯医药科技 股份有限公司2024年度财务报表时所复核的会计资料和经审计的财务报表的相关内容 进行了核对，在 ...

上海艾力斯医药科技股份有限公司 内部控制审计报告 2024年12月31日 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价 指引》的规定，建立健全和有效实施内部控制，并评价其有效性是企业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计 意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况 的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内 部控制审计结果推测未来内部控制的有效性具有一定风险。 内部控制审计报告 安永华明（2025）专字第80013571_B01号 上海艾力斯医药科技股份有限公司 上海艾力斯医药科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审 计了上海艾力斯医药科技股份有限公司2024年12月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 （本页无正文） 安永华明会计师事务所（特殊普通合伙） 中国注册会计师：吴慧珺 中国注册 ...

上海艾力斯医药科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为上海艾 力斯医药科技股份有限公司（以下简称"艾力斯"或"公司"）首次公开发行的 持续督导保荐人，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对公 司 2024 年度募集资金的存放和使用情况进行了专项核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 中信证券股份有限公司关于 根据中国证券监督管理委员会于 2020 年 10 月 12 日签发的证监许可 [2020]2559 号文《关于同意上海艾力斯医药科技股份有限公司首次公开发行股票 注册的批复》，公司在境内首次公开发行 90,000,000 股人民币普通股 A 股股票， 每股发行价格为人民币 22.73 元，股款以人民币缴足，计人民币 2,045,700,000.00 元，扣除承销及保荐费用、律师费、审计验资费、信息披露费以及其他发 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 3.1800 | 1.4300 | 122.38 | 0.2900 | | 每股净资产（元） | 11.74 | 8.85 | 32.66 | 7.08 | | 每股公积金(元) | 7.23 | 7.05 | 2.55 | 6.89 | | 每股未分配利润(元) | 2.77 | 0.51 | 443.14 | -0.84 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 35.58 | 20.18 | 76.31 | 7.91 | | 净利润(亿元) | 14.3 | 6.44 | 122.05 | 1.31 | | 净资产收益率(%) | 29.26 | 17.97 | 62.83 | 4.24 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 27506.31万股，累计占流通股比： 61 ...